close 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse. Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Change languageEesti
Ülevaade

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc
Search

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.19 1.71

Osta

Hinna uuendus 12. veebr 2026, 20:58 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.1400000000000001

Max

1.19

Põhinäitajad

By Trading Economics

Sissetulek

1.8M

-32M

Müük

-166K

1.7M

Kasumimarginaal

-1,852.384

Töötajad

181

EBITDA

7.9M

-29M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+335.71% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

3. märts 2026

Turustatistika

By TradingEconomics

Turukapital

3.5M

129M

Eelmine avamishind

-0.52

Eelmine sulgemishind

1.19

Uudiste sentiment

By Acuity

50%

50%

160 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. veebr 2026, 23:57 UTC

Kuumad aktsiad

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

DJ

Loe

12. veebr 2026, 23:35 UTC

Tulu
Suurimad hinnamuutused turgudel

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

DJ

Loe

12. veebr 2026, 23:28 UTC

Tulu

Applied Materials Profit Rises on Soaring AI Demand -- Update

DJ

Loe

12. veebr 2026, 21:47 UTC

Tulu

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

DJ

Loe

13. veebr 2026, 00:00 UTC

Market Talk

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

DJ

Loe

12. veebr 2026, 23:47 UTC

Market Talk

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

DJ

Loe

12. veebr 2026, 23:38 UTC

Market Talk

Gold Steady; Could Undergo Technical Recovery -- Market Talk

DJ

Loe

12. veebr 2026, 23:33 UTC

Tulu

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

DJ

Loe

12. veebr 2026, 23:09 UTC

Market Talk

South32's Hermosa Review Stokes Spending Fears -- Market Talk

DJ

Loe

12. veebr 2026, 22:55 UTC

Tulu
Kuumad aktsiad

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

DJ

Loe

12. veebr 2026, 22:46 UTC

Market Talk

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

DJ

Loe

12. veebr 2026, 22:23 UTC

Tulu

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

DJ

Loe

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

DJ

Loe

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

DJ

Loe

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

DJ

Loe

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

DJ

Loe

12. veebr 2026, 22:00 UTC

Tulu

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

DJ

Loe

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

DJ

Loe

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q Net $1.52B >AEM

DJ

Loe

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

DJ

Loe

12. veebr 2026, 22:00 UTC

Tulu

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

DJ

Loe

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

DJ

Loe

12. veebr 2026, 21:57 UTC

Tulu

XP 4Q Rev BRL4.95B >XP

DJ

Loe

12. veebr 2026, 21:52 UTC

Tulu

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

DJ

Loe

12. veebr 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

DJ

Loe

12. veebr 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Loe

12. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Loe

12. veebr 2026, 21:47 UTC

Tulu

Morningstar 4Q Rev $641M >MORN

DJ

Loe

12. veebr 2026, 21:39 UTC

Tulu

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

DJ

Loe

12. veebr 2026, 21:38 UTC

Tulu

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

335.71% tõus

12 kuu keskmine prognoos

Keskmine 4.88 USD  335.71%

Kõrge 8 USD

Madal 2 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

2

Osta

4

Hoia

0

Müü

Põhineb 6 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Very Strong Bullish Evidence

All events are bullish.

Pikk perspektiiv

No Evidence

There are no events.

Sentiment

By Acuity

160 / 352 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

1,037

↑ +2.17%

JNJ

Johnson and Johnson

244.47

↑ +1.48%

ABBV

AbbVie Inc

227.53

↑ +3.09%

NVS

Novartis AG

160.86

↑ +0.83%

MRK

Merck & Co Inc.

119.17

↓-0.13%
help-icon Live chat